drugset

drugset / Trial / NCT04611165

Concurrent Nivolumab and External Beam Radiation Therapy for Patients With Advanced HCC

NCT04611165 ↗

Phase 2 Completed 50 enrolled National Cancer Center, Korea Samsung Medical Center · collab

NaSingle-groupOpen-labelTreatment

Summary

To investigate the efficacy and safety of nivolumab for patients with advanced HCC undergoing EBRT

Timeline

Start: 2019-11-15
Primary completion: 2022-12-30
Completion: 2023-12-15

Publications

Kim BH, Park HC, Kim TH, Koh YH, Hong JY, Cho Y, Sinn DH, Park B, Park JW. Concurrent nivolumab and external beam radiation therapy for hepatocellular carcinoma with macrovascular invasion: A phase II study. JHEP Rep. 2023 Dec 21;6(4):100991. doi: 10.1016/j.jhepr.2023.100991. eCollection 2024 Apr.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Nivolumab	Monoclonal antibody	3 mg/kg	Intravenous

Indications